Form 4: Rocket Pharma CEO Sells Shares Under 10b5-1 Plan

Rocket Pharmaceuticals CEO Gaurav Shah sold 6,276 shares of common stock for $2.983 per share, as disclosed in a recent Form 4 filing.

Summary

• Gaurav Shah, CEO and Director of Rocket Pharmaceuticals, Inc. (RCKT), reported a sale of common stock.
• The transaction involved the disposition of 6,276 shares of common stock.
• The shares were sold at a price of $2.983 per share.
• The transaction occurred on November 18, 2025.
• This sale was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged transaction.
• Following the transaction, Shah directly beneficially owns 778,296 shares of common stock.
• Indirect beneficial ownership includes 207,897 shares held by his spouse and 198,341 shares held by the Gaurav D. Shah Irrevocable Trust.

Sentiment

Score: 5

Explanation: The filing reports a routine insider sale by the CEO under a pre-arranged 10b5-1 plan, which is a common practice for executive financial planning and diversification. It does not indicate a significant change in company fundamentals or management's view of the company's prospects.

Positives

• The sale was conducted under a Rule 10b5-1(c) plan, indicating a pre-arranged transaction for financial planning purposes rather than a reaction to new, undisclosed information.

Negatives

• CEO Gaurav Shah disposed of 6,276 shares of common stock, which can sometimes be perceived as a lack of confidence by investors, though mitigated by the 10b5-1 plan.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May view the CEO's sale of shares as a slight negative, though mitigated by the pre-arranged 10b5-1 plan, which suggests the sale is for personal financial planning rather than a reaction to company-specific news.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-scheduled sale of a relatively small number of shares by the CEO under a 10b5-1 plan. Such transactions are common for executive financial planning and diversification and do not typically signal a change in the company's fundamental outlook or management's confidence. Therefore, it does not warrant a change in investment recommendation based solely on this disclosure.

Keywords

ROCKET PHARMACEUTICALS, RCKT, Gaurav Shah, insider trading, Form 4, stock sale, CEO, director, beneficial ownership, 10b5-1 plan